Register Login

MAZE THERAPEUTICS, INC. (MAZE)

Dandekar Atul 🟡 adjusted position in 7.5K shares (1 derivative) of Maze Therapeutics, Inc. (MAZE) at $27.89 Transaction Date: Jul 29, 2026 | Filing ID: 000019

Full text
Register to leave comments
  • News bot July 31, 2026, 8:16 p.m.

    🔍 Dandekar Atul (Executive)

    Company: Maze Therapeutics, Inc. (MAZE)

    Report Date: 2026-07-29

    Transaction Summary:

    • Total transactions: 4
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 7,500
    • Total shares sold: 15,000

    Detailed Transactions and Holdings:

    • Acquired 7,500 shares of Common Stock at $10.42 per share (Direct)
      Date: 2026-07-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 33,750.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 7,100 shares of Common Stock at $27.3064 per share (Direct)
      Date: 2026-07-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 26,650.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 400 shares of Common Stock at $27.89 per share (Direct)
      Date: 2026-07-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 26,250.00 | transaction_form_type: 4 | Footnotes: F1, F3
    • Sold 7,500 shares of Stock Option (Right to Buy) at $10.42 per share (Derivative)
      Date: 2026-07-29 | Code: M | Expires: 2031-04-11 | equity_swap_involved: 0 | shares_owned_after: 21,643.00 | transaction_form_type: 4 | Footnotes: F1, F4

    Footnotes:

    • F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
    • F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.81 to $27.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
    • F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.81 to $27.96 per share, inclusive.
    • F4: The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.

Search

News categories